A detailed history of Federated Hermes, Inc. transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 554,214 shares of VYGR stock, worth $3.24 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
554,214
Previous 551,576 0.48%
Holding current value
$3.24 Million
Previous $5.14 Million 14.64%
% of portfolio
0.01%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$7.42 - $10.54 $19,573 - $27,804
2,638 Added 0.48%
554,214 $4.38 Million
Q4 2023

Jan 31, 2024

SELL
$6.28 - $8.81 $202,900 - $284,642
-32,309 Reduced 5.53%
551,576 $4.66 Million
Q3 2023

Nov 13, 2023

SELL
$7.55 - $11.25 $33,242 - $49,533
-4,403 Reduced 0.75%
583,885 $4.53 Million
Q2 2023

Aug 14, 2023

SELL
$6.94 - $13.99 $120,270 - $242,446
-17,330 Reduced 2.86%
588,288 $6.74 Million
Q1 2023

May 08, 2023

SELL
$6.0 - $10.78 $246 - $441
-41 Reduced 0.01%
605,618 $4.67 Million
Q4 2022

Feb 13, 2023

SELL
$4.94 - $6.61 $671 - $898
-136 Reduced 0.02%
605,659 $3.69 Million
Q3 2022

Nov 14, 2022

SELL
$5.57 - $7.47 $40,393 - $54,172
-7,252 Reduced 1.18%
605,795 $3.59 Million
Q2 2022

Aug 15, 2022

SELL
$4.82 - $10.09 $58,003 - $121,423
-12,034 Reduced 1.93%
613,047 $3.62 Million
Q1 2022

May 13, 2022

SELL
$2.75 - $9.44 $712 - $2,444
-259 Reduced 0.04%
625,081 $4.76 Million
Q4 2021

Feb 14, 2022

SELL
$2.47 - $5.55 $232,446 - $522,299
-94,108 Reduced 13.08%
625,340 $1.7 Million
Q3 2021

Nov 15, 2021

BUY
$2.63 - $4.12 $108,153 - $169,426
41,123 Added 6.06%
719,448 $1.89 Million
Q2 2021

Aug 16, 2021

BUY
$3.94 - $5.44 $1.6 Million - $2.2 Million
404,893 Added 148.08%
678,325 $2.8 Million
Q1 2021

May 13, 2021

SELL
$4.61 - $9.04 $164,719 - $323,008
-35,731 Reduced 11.56%
273,432 $1.29 Million
Q4 2020

Feb 12, 2021

SELL
$7.15 - $12.28 $1,537 - $2,640
-215 Reduced 0.07%
309,163 $2.21 Million
Q3 2020

Nov 12, 2020

BUY
$10.01 - $13.75 $494,844 - $679,731
49,435 Added 19.02%
309,378 $3.3 Million
Q2 2020

Aug 13, 2020

SELL
$8.05 - $14.21 $1.75 Million - $3.1 Million
-217,915 Reduced 45.6%
259,943 $3.28 Million
Q1 2020

May 13, 2020

SELL
$6.8 - $14.66 $3.73 Million - $8.03 Million
-547,964 Reduced 53.42%
477,858 $4.37 Million
Q4 2019

Feb 14, 2020

BUY
$12.82 - $16.85 $3.64 Million - $4.79 Million
284,022 Added 38.29%
1,025,822 $14.3 Million
Q3 2019

Nov 14, 2019

BUY
$16.31 - $28.29 $3.82 Million - $6.62 Million
234,022 Added 46.09%
741,800 $12.8 Million
Q2 2019

Aug 14, 2019

BUY
$19.18 - $27.88 $9.73 Million - $14.1 Million
507,369 Added 124051.1%
507,778 $13.8 Million
Q1 2019

May 10, 2019

SELL
$8.0 - $19.66 $26,592 - $65,349
-3,324 Reduced 89.04%
409 $8,000
Q4 2018

Feb 13, 2019

BUY
$8.59 - $18.05 $28,037 - $58,915
3,264 Added 695.95%
3,733 $35,000
Q3 2018

Nov 13, 2018

SELL
$17.11 - $21.74 $1,283 - $1,630
-75 Reduced 13.79%
469 $9,000
Q2 2018

Aug 10, 2018

SELL
$16.76 - $23.92 $4,558 - $6,506
-272 Reduced 33.33%
544 $11,000
Q1 2018

May 09, 2018

SELL
$16.16 - $31.31 $17,485 - $33,877
-1,082 Reduced 57.01%
816 $15,000
Q4 2017

Feb 14, 2018

BUY
$12.26 - $25.88 $23,269 - $49,120
1,898
1,898 $0

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $226M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.